As for COVID-19 incidence, JAKi users did not reach statistical significance (HR: 1.058, 95% CI: 0.895 to 1.250) than TNFi users.
← all excerpts
COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs.
1
—
—